Signal Pharmaceuticals

San Diego, United States Founded: 1993 • Age: 33 yrs Acquired By Celgene
Small molecule drugs regulating disease-associated genes are developed.

About Signal Pharmaceuticals

Signal Pharmaceuticals is a Healthcare company based in San Diego (United States) founded in 1993, and was acquired by Celgene in June 2000. Small molecule drugs regulating disease-associated genes are developed. Signal Pharmaceuticals has raised $12 million across 2 funding rounds from investors including New York Life Insurance, Celgene and Robertson Stephens Partners. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Drug Discovery. Its competitors include eGenesis, Beam Therapeutics and Korro Bio; 3 of its 3 listed competitors have raised funding.

Company details

Signal Pharmaceuticals was founded in 1993 in San Diego, United States, within the biotechnology sector. Research and development efforts are directed toward small molecule drugs that modulate disease-related genes. Advanced cellular, molecular, and genomic technologies are utilized to map gene-regulating pathways and identify proprietary targets for gene activation or deactivation. Partnerships with pharmaceutical companies are formed to advance drug discovery for disease-associated genes.

Key Metrics

Funding Insights of Signal Pharmaceuticals

Signal Pharmaceuticals has successfully raised a total of $12M across 2 strategic funding rounds. The most recent funding activity was a Series E round of $12 million completed in September 1997. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $12M
  • Total Rounds 2
  • Last Round Series E β€” $12M
  • Investors Count 5

All 2 funding rounds of Signal Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Sep 1997$12MSeries E––
Jun 1993Series D––
Valuation history

6 investors in total: 6 institutional.

Investors in Signal Pharmaceuticals

Signal Pharmaceuticals has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include New York Life Insurance, Celgene and Robertson Stephens Partners.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture capital firm focused on tech sectors
venrock.comPalo Alto, United States
Global financial advisory services are provided by the firm.
lehman.comNew York, United States
Mutual life insurance and asset management services are provided.
1845newyorklife.comNew York, United States
Wealth management firm
1978rscapital.comSan Francisco, United States
R&D company focused on manufacturing of drugs for multiple therapeutic areas
1997serono.comGeneva, Switzerland
Therapies for cancer and inflammatory diseases are developed.
1986celgene.comSummit, United States
Premium access

Investor details for Signal Pharmaceuticals

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Signal Pharmaceuticals

4 dated milestones of Signal Pharmaceuticals across 7 years, from founding to its latest funding, stage changes and deals.

  1. Founded Signal Pharmaceuticals is founded.
  2. Funding First funding round.
  3. Funding Latest funding round, Series E, of $12.0M.
  4. Exit Acquired by Celgene.

Competitors of Signal Pharmaceuticals

Signal Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include eGenesis, Beam Therapeutics and Korro Bio.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
egenesisbio.com2015Cambridge, United States$481.42M94
Gene transplantation platform for humanizing pig cells is developed.
beamtx.com2017Cambridge, United States$222M340
Developer of gene therapy using CRISPR base editing to treat diseases
korrobio.com2018Cambridge, United States$4M77
RNA-editing technologies are provided for precision medicine applications.
Premium access

Detailed competitors of Signal Pharmaceuticals

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Genomics & Gene Therapy Platforms

3 companies that operate in the same segment as Signal Pharmaceuticals (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Signal Pharmaceuticals

Premium access

Complete news archive for Signal Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Signal Pharmaceuticals

Signal Pharmaceuticals was founded in 1993.

Signal Pharmaceuticals is headquartered in San Diego, United States. It is registered at San Diego, California, United States.

Signal Pharmaceuticals is a funded company, having raised a total of $12M across 2 funding rounds to date.

Signal Pharmaceuticals was founded in 1993 in San Diego, United States, within the biotechnology sector. Research and development efforts are directed toward small molecule drugs that modulate disease-related genes. Advanced cellular, molecular, and genomic technologies are utilized to map gene-regulating pathways and identify proprietary targets for gene activation or deactivation. Partnerships with pharmaceutical companies are formed to advance drug discovery for disease-associated genes.

Signal Pharmaceuticals's top competitors include eGenesis, Korro Bio and Beam Therapeutics.

Signal Pharmaceuticals has 6 investors. Key investors include New York Life Insurance, Celgene, Robertson Stephens Partners, Ares Serono, and Lehman Brothers.

Yes. Signal Pharmaceuticals was acquired by Celgene in June 2000.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available